[go: up one dir, main page]

MX2022000778A - Proteina quimerica l1 del virus de papiloma humano. - Google Patents

Proteina quimerica l1 del virus de papiloma humano.

Info

Publication number
MX2022000778A
MX2022000778A MX2022000778A MX2022000778A MX2022000778A MX 2022000778 A MX2022000778 A MX 2022000778A MX 2022000778 A MX2022000778 A MX 2022000778A MX 2022000778 A MX2022000778 A MX 2022000778A MX 2022000778 A MX2022000778 A MX 2022000778A
Authority
MX
Mexico
Prior art keywords
papilloma virus
protein
proteins
chimeric
type
Prior art date
Application number
MX2022000778A
Other languages
English (en)
Inventor
Ping Hu
Wei Zhang
Liangzhi Xie
Chunxia Luo
Xiaoyan Suo
Lin Pang
Original Assignee
Sinocelltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinocelltech Ltd filed Critical Sinocelltech Ltd
Publication of MX2022000778A publication Critical patent/MX2022000778A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con proteínas quiméricas L1 de virus de papiloma y polinucleótidos que codifican de las mismas y también con partículas similares a virus de VPH y los métodos de preparación de los mismos. La proteína quimérica L1 del virus de papiloma comprende un fragmento N-terminal derivado de la proteína L1 del primer tipo de virus de papiloma, el fragmento N-terminal mantiene la inmunogenicidad de la proteína L1 del tipo de VPH correspondiente; y un fragmento C-terminal derivado de la proteína L1 del segundo tipo de virus de papiloma, la proteína L1 del segundo tipo de virus de papiloma tiene un mejor nivel de expresión y una mejor solubilidad comparada con las proteínas L1 u otros tipos de VPH; en donde las proteínas quiméricas L1 de virus de papiloma tienen la inmunogenicidad de las proteínas L1 de los tipos de VPH correspondientes. Las proteínas quiméricas L del virus del papiloma tienen una mejor cantidad de expresión y solubilidad para la producción en masa de las vacunas.
MX2022000778A 2019-07-19 2020-07-17 Proteina quimerica l1 del virus de papiloma humano. MX2022000778A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910656278 2019-07-19
PCT/CN2020/102603 WO2021013073A1 (zh) 2019-07-19 2020-07-17 嵌合的乳头瘤病毒l1蛋白

Publications (1)

Publication Number Publication Date
MX2022000778A true MX2022000778A (es) 2022-02-14

Family

ID=74193236

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000778A MX2022000778A (es) 2019-07-19 2020-07-17 Proteina quimerica l1 del virus de papiloma humano.

Country Status (14)

Country Link
US (12) US12139514B2 (es)
EP (1) EP4001297B1 (es)
JP (2) JP7805920B2 (es)
KR (2) KR102767403B1 (es)
CN (1) CN114364692B (es)
AU (1) AU2020318114B2 (es)
ES (1) ES3034186T3 (es)
HR (1) HRP20250701T1 (es)
MX (1) MX2022000778A (es)
MY (1) MY197457A (es)
PL (1) PL4001297T3 (es)
RS (1) RS66886B1 (es)
WO (1) WO2021013073A1 (es)
ZA (1) ZA202201570B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020318114B2 (en) * 2019-07-19 2024-07-11 Sinocelltech Ltd. Chimeric papillomavirus L1 protein
EP4292607A4 (en) * 2021-01-14 2024-12-11 Sinocelltech Ltd. STABLE PREPARATION OF A VACCINE CONTAINING VIRUS-LIKE PARTICLES OF THE HUMAN PAPILLOMAVIRUS
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113106107A (zh) * 2021-04-23 2021-07-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 35l1的多核苷酸及其表达载体、宿主细胞和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
PT757717E (pt) 1994-05-16 2006-09-29 Merck & Co Inc Vacinas de papilomavirus
AU4270196A (en) 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
WO2004062584A2 (en) * 2003-01-10 2004-07-29 Regents Of The University Of Colorado Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
KR100959145B1 (ko) * 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
KR102351259B1 (ko) * 2015-12-04 2022-01-14 시아먼 유니버시티 58형 인유두종 바이러스 엘1 단백질의 돌연변이체
CN107188966B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN107188967B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
WO2019011331A1 (zh) * 2017-07-14 2019-01-17 厦门大学 一种人乳头瘤病毒16型l1蛋白的突变体
AU2020318114B2 (en) * 2019-07-19 2024-07-11 Sinocelltech Ltd. Chimeric papillomavirus L1 protein

Also Published As

Publication number Publication date
PL4001297T3 (pl) 2025-09-08
EP4001297B1 (en) 2025-05-14
JP7805920B2 (ja) 2026-01-26
ES3034186T3 (en) 2025-08-13
JP2024009010A (ja) 2024-01-19
US20250136645A1 (en) 2025-05-01
US20250145671A1 (en) 2025-05-08
MY197457A (en) 2023-06-19
KR20220071180A (ko) 2022-05-31
HRP20250701T1 (hr) 2025-09-12
US12139514B2 (en) 2024-11-12
US20250122246A1 (en) 2025-04-17
US20250136644A1 (en) 2025-05-01
CN114364692A (zh) 2022-04-15
CN114364692B (zh) 2024-03-29
RS66886B1 (sr) 2025-07-31
US20250092096A1 (en) 2025-03-20
ZA202201570B (en) 2025-09-25
EP4001297C0 (en) 2025-05-14
KR102767403B1 (ko) 2025-02-14
KR102640490B1 (ko) 2024-02-28
EP4001297A4 (en) 2023-09-27
BR112022001075A2 (pt) 2022-03-29
US20250122245A1 (en) 2025-04-17
JP2022540951A (ja) 2022-09-20
CA3147850A1 (en) 2021-01-28
US20250145672A1 (en) 2025-05-08
US20220281925A1 (en) 2022-09-08
EP4001297A1 (en) 2022-05-25
KR20240011248A (ko) 2024-01-25
US20250136646A1 (en) 2025-05-01
US20250109174A1 (en) 2025-04-03
AU2020318114B2 (en) 2024-07-11
US20250101068A1 (en) 2025-03-27
US20250171506A1 (en) 2025-05-29
WO2021013073A1 (zh) 2021-01-28
AU2020318114A1 (en) 2022-02-10
JP7696977B2 (ja) 2025-06-23

Similar Documents

Publication Publication Date Title
MX2022000778A (es) Proteina quimerica l1 del virus de papiloma humano.
WO2020193688A3 (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
CO2017004838A2 (es) Vacunas terapéuticas contra el vph16
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
WO2007011904A3 (en) Recombinant flu vaccines
AR108781A1 (es) Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
PE20142330A1 (es) Vacuna de peptido ch3 de ige
MX2017001017A (es) Vacunas y anticuerpos contra el dengue.
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
EA201892735A1 (ru) Состав вакцины против hiv
MX2020011586A (es) Virus vaccinia quimerico sintetico.
EP2589604A4 (en) SHORTEN L1 PROTEIN OF THE TYPE 52 HUMAN PAPILLOMA VIRUS
PH12020552197A1 (en) Influenza virus hemagglutinin mutants
WO2017132332A8 (en) Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes
MX2021007285A (es) Particulas similares a virus del cmv modificadas por fusion.
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
MX363149B (es) Vacunas de nucleoproteina de la influenza.
MX390966B (es) Vacunas contra el dengue
NZ751943A (en) Hepatitis c virus immunogenic compositions and methods of use thereof
ZA202201571B (en) Polyvalent immunogenicity composition for human papillomavirus
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
JP2019506168A5 (es)
CL2013002631A1 (es) Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura.